Printed from http://www.researchandmarkets.com/reports/2020184
Analysis of the Anticoagulant Market
This Frost & Sullivan research service titled Analysis of the Anticoagulant Market provides an overview of industry trends and marketed product revenue forecasts. The study includes a complete analysis of key market drivers, restraints, and challenges. In this research, Frost & Sullivan's expert analysts thoroughly examine the following segments: oral (VKAs, factor Xa inhibitors, and direct thrombin inhibitors) and parenteral (indirect thrombin inhibitors, and direct thrombin inhibitors).
Large Atrial Fibrillation Population with Unmet Needs Will Help the U.S. Anticoagulant Market to Grow to $10 billion by 2016
Rollout of Novel Oral Anticoagulants Poised to Drastically Change the Clinical Practice Landscape
The U.S. anticoagulant market is on the verge of a major shift in clinical practice. It is transitioning from a market dominated by a single injectable anticoagulant to a highly competitive one dominated by first-in-class novel oral anticoagulants. Companies are vying with each other to introduce novel therapies that offer superior safety, efficacy, and convenience to patients and physicians. This is a medical need that has been unmet for decades. “Studies reveal that there are currently 2.7 million patients in the United States with atrial fibrillation (AF); however, this may be an underestimation as the actual figure could be as high as 4.0 million,” notes the analyst of this research service. “Lifelong anticoagulant therapy is critical for stroke prevention in these patients, resulting in substantial commercial opportunities.” Warfarin, the long-established gold standard therapy for stroke prevention in AF, carries many significant inherent risks such as bleeding, leaving a very narrow therapeutic window.
A robust growth period is expected following the launch of Pradaxa (dabigatran), an oral direct thrombin inhibitor (DTI) in late 2010, followed by a second growth period upon the anticipated launch of Eliquis (apixaban), an oral factor Xa inhibitor in late 2012 or early 2013. Edoxaban, an oral factor Xa inhibitor is also in the pipeline, and Xarelto (rivaroxaban), another oral factor Xa inhibitor which is approved for prophylaxis following orthopedic surgery, is awaiting approval for stroke prevention. These agents are poised to dominate the market for stroke prevention in AF, a very large and partially untapped market. They are also likely to grab substantial market share from the parenteral anticoagulants for prophylaxis of venous thromboembolism in orthopedic joint replacement surgery. With the approval of Pradaxa and the imminent approval of its successors, the bar has been significantly raised for the anticoagulant market. Superiority to warfarin is paramount for new drug approval and market uptake. Patient and clinician acceptance will depend on strong data showing improvements in efficacy and lower risk of bleeding.
There is a fine line between the prevention of thrombosis and uncontrollable bleeding. Most often, bleeding issues or other safety concerns may not arise until late-stage clinical trials, or only in certain patient populations, after significant investments in drug development have been made. In addition, bleeding issues or other safety concerns may surface in the future, particularly if the bleeding risk of the real-world population differs from that studied in clinical trials, leading to black-box warnings or market withdrawal.
One of the shortcomings of oral anticoagulants is the lack of a strategy for reversal in case of emergency or uncontrolled bleeding. “The oral anticoagulants are ideal for chronic therapy with their easy administration,” says the analyst. “However, the ability to quickly reverse the anticoagulant action in the event of an emergency is a critical unmet need.” Newcomers to the market that can address this issue will resolve the key shortfall of chronic anticoagulation therapy and their drugs are likely see rapid adoption into clinical practice.
Expert Frost & Sullivan analysts thoroughly examine the following market sectors in this research:
- Oral (VK, factor Xa inhibitors, direct thrombin inhibitors)
- Parenteral (indirect thrombin inhibitors, and direct thrombin inhibitors
The following technologies are covered in this research:
- Subcutaneous injection
- Oral administration
- Intravenous administration
- Coagulation monitoring
2. Market Overview
3. Total Market
3.1 External Challenges: Drivers and Restraints
3.2 Forecasts and Trends
3.3 Demand Analysis
3.4 Market Share and Competitive Analysis
4 Parenteral Anticoagulant Segment Breakdown
5. Oral Anticoagulant Segment Breakdown
6. The Last Word (Conclusions and Implications)
71. Relevant KOL Commentary
7.2 Product Level Market Share Analysis
Order by Fax - using the order form below
Order By Post - print the order form below and send to
Research and Markets,
Fax order form
To place a fax order simply print this form, fill in and fax the completed form to the number below. If you have any questions please email firstname.lastname@example.org
Please verify that the product information is correct and select the format you require.
Analysis of the Anticoagulant Market
Please enter the quantity of the report format you require.
|Electronic (PDF) - Site License||EUR 4427|
|Electronic (PDF) - Enterprisewide||EUR 5534|
|Electronic and Hard Copy (PDF) - Site License||EUR 4796 + EUR€ 50.00 Shipping/Handling *|
|Electronic and Hard Copy (PDF) - Enterprisewide||EUR 5903 + EUR€ 50.00 Shipping/Handling *|
* Shipping/Handling is only charged once per order.
Please enter all the information below in block capitals.
Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)
Please indicate the payment method you would like to use by selecting the appropriate box.
Please post the check, accompanied by this form, to:
Research and Markets,
Please transfer funds to:
27-35 Main Street
If you have a Marketing Code please enter it below:
Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp